Somia P. Hickman

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 10 papers. Top paper: “Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial”.

Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial

The Lancet(2023)10.1016/s0140-6736(22)02400-x

N/A

4.3DataRank · unranked

65 citations

Katherine V. Houser, Amelia R. Hofstetter, Ana M. Ortega‐Villa, Christine Lee, Anne Preston +50 more

Safety and immunogenicity of a ferritin nanoparticle H2 influenza vaccine in healthy adults: a phase 1 trial

Nature Medicine(2022)10.1038/s41591-021-01660-8

N/A

3.6DataRank · unranked

165 citations

Grace Chen, Cristina Carter, Michelle C. Crank, Thuy Nguyen, Maria Claudia Burgos Florez +70 more

Low-Dose Subcutaneous or Intravenous Monoclonal Antibody to Prevent Malaria

New England Journal of Medicine(2022)10.1056/nejmoa2203067

N/A

3.6DataRank · unranked

125 citations

Azza H. Idris, Nina M. Berkowitz, Myra Happe, Martin R. Gaudinski, Christian Buettner +42 more

Subcutaneous Administration of a Monoclonal Antibody to Prevent Malaria

New England Journal of Medicine(2024)10.1056/nejmoa2312775

N/A

2.6DataRank · unranked

84 citations

Aïssata Ongoïba, Anne C Preston, Sara A. Healy, Zonghui Hu, Jeff Skinner +38 more

Safety, tolerability, and immunogenicity of the respiratory syncytial virus prefusion F subunit vaccine DS-Cav1: a phase 1, randomised, open-label, dose-escalation clinical trial

The Lancet Respiratory Medicine(2021)10.1016/s2213-2600(21)00098-9

N/A

2.5DataRank · unranked

67 citations

Kaitlyn M. Morabito, Emily Phung, Michelle C. Crank, Pamela Costner, LaSonji A. Holman +74 more

Low-dose intravenous and subcutaneous CIS43LS monoclonal antibody for protection against malaria (VRC 612 Part C): a phase 1, adaptive trial

The Lancet Infectious Diseases(2023)10.1016/s1473-3099(22)00793-9

N/A

1.2DataRank · unranked

41 citations

Andrea A. Berry, Kaitlin Mason, Azza H. Idris, Mark O’Callahan, Myra Happe +95 more

Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial

The Lancet Infectious Diseases(2023)10.1016/s1473-3099(23)00344-4

N/A

1.0DataRank · unranked

24 citations

Katherine V. Houser, Amelia R. Hofstetter, Ana M. Ortega‐Villa, Prossy Naluyima, Francis Kiweewa +70 more

Phase 1 trial evaluating safety and pharmacokinetics of HIV-1 broadly neutralizing mAbs 10E8VLS and VRC07-523LS

JCI Insight(2024)10.1172/jci.insight.175375

N/A

0.404DataRank · unranked

7 citations

Amarendra Pegu, Larisa Strom, Cristina Carter, Cynthia S. Hendel, LaSonji A Holman +32 more

Safety and pharmacokinetics of N6LS, a broadly neutralising monoclonal antibody for HIV: a phase 1, open-label, dose-escalation study in healthy adults

The Lancet HIV(2025)10.1016/s2352-3018(25)00041-4

N/A

0.335DataRank · unranked

8 citations

Katherine V. Houser, Martin R. Gaudinski, Alicia T. Widge, Seemal F. Awan, Cristina Carter +95 more

Vaccination with prefusion-stabilized respiratory syncytial virus fusion protein induces genetically and antigenically diverse antibody responses

Immunity(2021)10.1016/j.immuni.2021.03.004

N/A

0DataRank · unranked

70 citations

Daniel Wrapp, Chen‐Hsiang Shen, Morgan S. A. Gilman, Tracy J. Ruckwardt, Chaim A. Schramm +30 more